A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies. Objective: This double‐blind, placebo‐controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder. Methods: Subjects (n = 457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10 mg once daily. The primary efficacy endpoint was reduction in Hamilton Anxiety Scale (HAM‐A) total scores from baseline after 8 weeks of treatment. Key secondary outcomes were changes from baseline in HAM‐A total scores for the 2.5 and 10 mg dose, Hospital Anxiety and Depression anxiety subscore, 36‐Item Short‐Form Health Survey, Sheehan Disability Scale, and Clinical Global Impression‐Improvement Scale score, as well as HAM‐A response rate at week 8. Results: Neither vortioxetine dose achieved a statistically significant improvement over placebo on the primary endpoint (least‐squares mean difference ± standard error from placebo: –0.87 ± 0.803 [p = 0.279] for 2.5 mg and −0.81 ± 0.791 [p = 0.306] for 10 mg vortioxetine) or on any secondary efficacy endpoints. Common adverse events (≥5% in either vortioxetine group) were nausea, dry mouth, headache, diarrhea, constipation, and vomiting. Conclusions: Vortioxetine 2.5 and 10 mg treatment did not significantly improve generalized anxiety disorder symptoms versus placebo. Vortioxetine was safe and well tolerated in this patient population. Copyright © 2014 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · cited 1×
“In vitro studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundMørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225 · cited 4×
“The rationale for investigating vortioxetine in subjects with GAD was based on positive results in a study (Alvarez et al., 2012) conducted in subjects with MDD with high levels of anxiety symptoms (mean baseline HAM-A total scores = 22.”
MethodResultInfluentialBoulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P., Chen, Y., & Thase, M. E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07470 · Cited by 150
Self-citationJain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
Self-citationBoulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127 · cited 1×
“There has been a tendency across studies to see increasing efficacy at higher doses (Henigsberg et al., 2012; Boulenger et al., 2012, 2013).”
Background
Cited by
Stein, M. B., & Sareen, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmcp1502514 · Cited by 314
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., & Chen, Y.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2014-01
- Volume
- 29
- Issue
- 1
- Pages
- 64-72
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2129162473
- Cited by
- 44
- References
- 8
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. https://app.cochat.ai/papers/10.1002/hup.2371
- The paper
- Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., & Chen, Y. (2014). A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.2371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.